# Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma

Source: https://onco.cc/trials/nct06784648/  
OnCo record `nct06784648` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Pembrolizumab, Ipilimumab in melanoma and uveal melanoma, run by BioInvent International AB, active and no longer recruiting.

## Summary

Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma is a phase 1/2 interventional study registered as NCT06784648 by BioInvent International AB, with 35 participants planned, started 2024-12-11 and due to reach its primary completion in 2025-12-30. Interventions recorded: pembrolizumab (KEYTRUDA®), BI-1607, Ipilimumab (YervoyTM, 50 mg/10 mL solution). Conditions listed: Melanoma Metastatic, Melanoma of Skin, Melanoma BRAF V600E/K Mutated, Melanoma Recurrent. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06784648
- Phase: 1/2
- Setting: An Open-Label, Multicentre Phase 1B/2A Clinical Trial of BI-1607, an Fc-Engineered Monoclonal Antibody to FcγRIIB (CD32B) in Combination With Ipilimumab and Pembrolizumab in Participants With Unresectable or Metastatic Melanoma
- Sponsor: BioInvent International AB
- Enrolled: 35

## Sources

- ClinicalTrials.gov NCT06784648: https://clinicaltrials.gov/study/NCT06784648

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/), [Uveal melanoma](https://onco.cc/cancers/uveal-melanoma/)
- drugs: [Ipilimumab](https://onco.cc/drugs/ipilimumab/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- companies: [BioInvent International](https://onco.cc/companies/bioinvent-international/)

---
JSON: https://onco.cc/api/v1/entities/nct06784648.json